Sheffield Institute for Translational Neuroscience are hopeful that new research (published in Brain) may lead to a group of drugs that may slow the progression of Parkinson’s disease.
One of the major hypotheses for brain cell death in Parkinson’s is the malfunctioning of the mitochondria. The drug studied by the researchers at the Sheffield Institute includes compounds targeted to correct the faulty mitochondria, the power house of the cells of our body.
The synthetic drug identified by researchers, ‘Ursodeoxycholic acid‘ (UDCA), is a licensed drug has been used to treat liver disease. Researchers can now initiate clinical trials to verify the safety as well as the tolerability for Parkinson’s.
How exciting is this? Treatment options that will slow down or halt Parkinson’s progression – rather than just managing symptoms – have serious implications for improved quality of life! I’m looking forward to how the clinical trials progress! much love.